WO2009143371A3 - Compositions comportant un arnsi des voies mtor et leurs procédés d’utilisations - Google Patents

Compositions comportant un arnsi des voies mtor et leurs procédés d’utilisations Download PDF

Info

Publication number
WO2009143371A3
WO2009143371A3 PCT/US2009/044891 US2009044891W WO2009143371A3 WO 2009143371 A3 WO2009143371 A3 WO 2009143371A3 US 2009044891 W US2009044891 W US 2009044891W WO 2009143371 A3 WO2009143371 A3 WO 2009143371A3
Authority
WO
WIPO (PCT)
Prior art keywords
methods
compositions
mtor sirna
mtor
sirna
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US2009/044891
Other languages
English (en)
Other versions
WO2009143371A2 (fr
Inventor
Frank Y. Xie
Xiaodong Yang
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Silence Therapeutics PLC
Original Assignee
Intradigm Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Intradigm Corp filed Critical Intradigm Corp
Publication of WO2009143371A2 publication Critical patent/WO2009143371A2/fr
Publication of WO2009143371A3 publication Critical patent/WO2009143371A3/fr
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C12N15/1137—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y207/00—Transferases transferring phosphorus-containing groups (2.7)
    • C12Y207/11—Protein-serine/threonine kinases (2.7.11)
    • C12Y207/11001—Non-specific serine/threonine protein kinase (2.7.11.1), i.e. casein kinase or checkpoint kinase
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/14—Type of nucleic acid interfering nucleic acids [NA]

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Zoology (AREA)
  • General Health & Medical Sciences (AREA)
  • General Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Wood Science & Technology (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Plant Pathology (AREA)
  • Biophysics (AREA)
  • Virology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

La présente invention concerne des molécules d’acides nucléiques inhibitrices de l’expression de mTOR. L’invention concerne également des procédés d’utilisation des molécules d’acides nucléiques.
PCT/US2009/044891 2008-05-21 2009-05-21 Compositions comportant un arnsi des voies mtor et leurs procédés d’utilisations Ceased WO2009143371A2 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US5495908P 2008-05-21 2008-05-21
US61/054,959 2008-05-21

Publications (2)

Publication Number Publication Date
WO2009143371A2 WO2009143371A2 (fr) 2009-11-26
WO2009143371A3 true WO2009143371A3 (fr) 2010-01-14

Family

ID=41202671

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2009/044891 Ceased WO2009143371A2 (fr) 2008-05-21 2009-05-21 Compositions comportant un arnsi des voies mtor et leurs procédés d’utilisations

Country Status (1)

Country Link
WO (1) WO2009143371A2 (fr)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2018048046A2 (fr) * 2016-09-09 2018-03-15 (주)씨드모젠 Composition pharmaceutique contenant un inhibiteur de mtor pour le traitement de la dégénérescence maculaire
JP6931046B2 (ja) 2016-09-09 2021-09-01 シドゥモゼン・カンパニー・リミテッド ｍＴＯＲ阻害剤を含有する黄斑変性治療用薬学組成物
EP3551641A4 (fr) 2016-12-08 2021-01-13 University of Utah Research Foundation Agents de la staufen1 et procédés associés
EP3807291A4 (fr) * 2018-06-14 2022-02-23 University of Utah Research Foundation Agents de régulation de staufen1 et procédés associés
AU2022422864A1 (en) * 2021-12-21 2024-07-04 Suzhou Ribo Life Science Co., Ltd. Nucleic acid, composition and conjugate containing nucleic acid, preparation method therefor and use thereof
KR20240126870A (ko) 2021-12-22 2024-08-21 캠프4 테라퓨틱스 코포레이션 조절 rna들을 표적으로 하는 안티센스 올리고뉴클레오티드를 사용한 유전자 전사의 조절

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005023202A2 (fr) * 2003-09-09 2005-03-17 Beth Israel Deaconess Medical Center, Inc. Activation directe de la kinase activee par l'amp reposant sur l'utilisation de la kinase lkb1, suppresseur de tumeurs
US20060234249A1 (en) * 2005-04-15 2006-10-19 Immusol Incorporated Novel assays for assessing cancerous cell growth
WO2008109364A2 (fr) * 2007-03-02 2008-09-12 Mdrna, Inc. Composés d'acide nucléique permettant d'inhiber l'expression de gène frap1 et utilisations de ceux-ci

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005023202A2 (fr) * 2003-09-09 2005-03-17 Beth Israel Deaconess Medical Center, Inc. Activation directe de la kinase activee par l'amp reposant sur l'utilisation de la kinase lkb1, suppresseur de tumeurs
US20060234249A1 (en) * 2005-04-15 2006-10-19 Immusol Incorporated Novel assays for assessing cancerous cell growth
WO2008109364A2 (fr) * 2007-03-02 2008-09-12 Mdrna, Inc. Composés d'acide nucléique permettant d'inhiber l'expression de gène frap1 et utilisations de ceux-ci

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
HOU ET AL: "An activated mTOR/p70S6K signaling pathway in esophageal squamous cell carcinoma cell lines and inhibition of the pathway by rapamycin and siRNA against mTOR", CANCER LETTERS, NEW YORK, NY, US, vol. 253, no. 2, 10 July 2007 (2007-07-10), pages 236 - 248, XP022144286, ISSN: 0304-3835 *
IWAMARU A ET AL: "Silencing mammalian target of rapamycin signaling by small interfering RNA enhances rapamycin-induced autophagy in malignant glioma cells", ONCOGENE, NATURE PUBLISHING GROUP, GB, vol. 26, no. 13, 25 September 2006 (2006-09-25), pages 1840 - 1851, XP002497598, ISSN: 0950-9232, [retrieved on 20060925] *
KE N ET AL: "A new inducible RNAi xenograft model for assessing the staged tumor response to mTOR silencing", EXPERIMENTAL CELL RESEARCH, ACADEMIC PRESS, US, vol. 312, no. 15, 10 September 2006 (2006-09-10), pages 2726 - 2734, XP024945163, ISSN: 0014-4827, [retrieved on 20060910] *

Also Published As

Publication number Publication date
WO2009143371A2 (fr) 2009-11-26

Similar Documents

Publication Publication Date Title
WO2009108217A3 (fr) Compositions comprenant un arnsi de k-ras et procédés d’utilisation
WO2009039189A3 (fr) Compositions comprenant des arnsi de stat3 et leurs procédés d'utilisation
WO2009114475A3 (fr) Compositions comprenant de la pcsk9 humaine et un siarn d’apolipoprotéine b, et procédés d’utilisation de celles-ci
WO2009002440A3 (fr) Compositions comprenant un arnsi de egfr humain et leurs procédés d'utilisation
AU2017248555B2 (en) Closed nucleic acid structures
WO2012024526A3 (fr) Conjugués, particules, compositions et procédés associés
WO2010018563A3 (fr) Compositions et procédés de pronostic d'un lymphome
GB0922209D0 (en) Proteins, nucleic acid molecules and compositions
WO2010062863A3 (fr) Compositions contenant des satiogènes et leurs procédés d'utilisation
WO2011079902A3 (fr) Matériaux biologiques et utilisations de ceux-ci
WO2009111676A3 (fr) Petites molécules contenant du bore utilisées en tant qu'agents anti-inflammatoires
HK1205751A1 (en) Conjugates, particles, compositions, and related methods
WO2011156654A3 (fr) Caractérisation de voies de cellules
GB201014134D0 (en) Methods of RNA aplification in the presence of DNA
WO2011160052A3 (fr) Procédés et compositions associés à des arn-endonucléases spécifiques d'une séquence
WO2009114724A3 (fr) COMPOSITIONS COMPRENANT DU SIARN DE FACTEUR NUCLÉAIRE-KAPPA B (NF-ĸB), ET PROCÉDÉS D’UTILISATION DE CEUX-CI
WO2009111586A3 (fr) Évolution autonome in vitro
WO2010011331A3 (fr) Compositions et procédés se rapportant à la fonction sirt1
WO2010039802A3 (fr) Procédés et compositions pour isoler un acide nucléique
EP2318508A4 (fr) Détermination de l intégrité d arn
WO2007106915A8 (fr) Anticorps à efgl 7 et leurs procédés d'utilisation
WO2009143277A3 (fr) Compositions comprenant un arnsi hscn9a et leurs procédés d'utilisation
WO2011140334A3 (fr) Composés, méthodes de fabrication ou d'identification de composés et leurs utilisations
WO2011050188A8 (fr) Anticorps anti-hepsine et procédés d'utilisation de ceux-ci
WO2011103028A3 (fr) Compositions et méthodes d'inhibition de mmset

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 09751599

Country of ref document: EP

Kind code of ref document: A2

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 09751599

Country of ref document: EP

Kind code of ref document: A2